Search results for "From ACP Journal Club"

Results 41 - 50 of about 116 for "From ACP Journal Club".
Sort by: Relevance | Newest | Oldest

In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function

The results of the CANVAS trial are promising for patients with type 2 diabetes mellitus (T2DM) and early chronic kidney disease, but ongoing research should provide more convincing data, said an ACP Journal Club commentary.
8 Mar 2019

Risk scores overestimated risk for CVD in newly diagnosed type 2 diabetes

Available risk scores are in need of recalibration but still serve as useful decision-making tools, according to an ACP Journal Club commentary.
14 Dec 2018

SGLT-2 inhibitors were not linked to severe or nonsevere UTIs vs DPP-4 inhibitors or GLP-1 agonists

An ACP Journal Club commentary called the results of this real-world, retrospective study reassuring regarding concerns about associations of urinary tract infections (UTIs) with sodium-glucose cotransporter-2 (SGLT-2) inhibitors.
10 Jan 2020

Review: Evidence is inconclusive on metabolic surgery vs. medical treatment for microvascular complications in T2DM

A meta-analysis from earlier this year that compared the effects of metabolic surgery and medical treatment found 10 studies to include, only three of them randomized controlled trials.
10 Aug 2018

In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER

Exenatide is still an effective alternative for patients who cannot tolerate semaglutide due to gastrointestinal adverse events, noted the ACP Journal Club commentary.
11 May 2018

In high-risk T1DM, real-time continuous glucose monitoring vs self-monitoring reduced hypoglycemic events

The study provides compelling evidence for clinicians to recommend real-time continuous glucose monitoring to their patients at high risk for severe hypoglycemia, the ACP Journal Club commentary said.
8 Jun 2018

Intensive weight management in primary care improved weight loss and remission of type 2 diabetes

The author of an ACP Journal Club commentary said that the intervention effect was strong enough to prompt a reconsideration of primary care management of obesity and that the results of the trial may motivate patients to lose enough weight to reverse diabetes.
13 Apr 2018

In type 2 diabetes with CVD and kidney disease, empagliflozin reduced mortality and hospitalization

If the results are confirmed, sodium–glucose co-transporter-2 inhibitors will become a dominant strategy over standard glucose-lowering therapies for treating diabetic kidney disease, according to the ACP Journal Club commentary.
8 Jun 2018

Review compares effectiveness, cost, and safety of second-line drugs for diabetes

The review found that sulfonylureas were more cost-effective than newer agents, but an ACP Journal Club commentary stressed the importance of shared decision making in the choice of a second agent.
9 Feb 2018

Two reviews analyze efficacy of newer drug classes in type 1 and type 2 diabetes

The evidence favors glucagon-like peptide 1 agonists and, particularly, sodium–glucose cotransporter 2 inhibitors for type 2 diabetes, but the benefits in type 1 diabetes remain speculative, said an ACP Journal Club commentary.
10 Aug 2018

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next